OPENINGS® Patient Support Program

Openings®
Patient Support Program from Alcon

JOIN NOW

A helping hand can go a long way.
Learn about the benefits of our patient support program.

Click here for savings card Terms and Conditions

Savings Card

Eligible commercially insured patients pay no more than $25* for their Alcon prescription

Your savings card can help make it a little easier to stay on track with your TRAVATAN Z® Solution (travoprost ophthalmic solution) 0.004%, SIMBRINZA® Suspension (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, or AZOPT® Suspension (brinzolamide ophthalmic suspension) 1% by helping to make your refills more affordable.

- If you fill your prescription each month with commercial insurance, you pay no more than $25 and Alcon will pay the remaining cost, up to $105 for each 30-day supply.
- If you fill your prescription every 3 months with commercial insurance, you pay no more than $50 and Alcon will pay the remaining cost, up to $365 for each 90-day supply.

Join now ›

Learn how to use your savings card
Using your savings card from the OPENINGS® Patient Support Program is easy. If eligible, simply take your activated savings card to the pharmacy (click here if you need to activate your card) along with your prescription. The savings card is good for multiple uses and can be used for prescriptions of TRAVATAN Z® Solution, SIMBRINZA® Suspension and AZOPT® Suspension. Be sure to present your savings card at the pharmacy each time you fill your prescription for any of these products.

If your pharmacy does not accept your savings card or you are using a mail order pharmacy please contact the McKesson Help Desk at 1-844-236-8027 (8:00am - 8:00pm ET, Monday - Friday) for assistance or visit www.patientrebateonline.com. You will need to have your savings card available when reaching out for assistance.

Click here for full savings card Terms and Conditions ›

Join now ›

Helpful Information

We are here to help you with the job of managing your eye pressure by sending you emails and mailers filled with practical tips, educational information, and encouragement.

Join now ›

Reminder Service

Get convenient refill alerts because your eyedrops can't work if you don't use them, so don't risk running out!

Join now ›

Get support from the OPENINGS® Patient Support Program JOIN NOW

Important information about TRAVATAN Z® (travoprost ophthalmic solution) 0.004%

INDICATIONS AND USAGE

TRAVATAN Z® Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosing and Administration

The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® Solution should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect.

TRAVATAN Z® Solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Pigmentation - Travoprost ophthalmic solution has been reported to increase the pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to

Important information about SIMBRINZA® (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%

INDICATIONS AND USAGE

SIMBRINZA® Suspension is a fixed combination indicated in the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and Administration

The recommended dose is one drop of SIMBRINZA® Suspension in the affected eye(s) three times daily. Shake well before use. SIMBRINZA® Suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION

Contraindications

SIMBRINZA® Suspension is contraindicated in patients who are hypersensitive to any component of this product and neonates and infants under the age of 2 years.

Warnings and Precautions

Sulfonamide Hypersensitivity Reactions - Brinzolamide is a sulfonamide, and although

Important information about AZOPT® (brinzolamide ophthalmic suspension) 1%

INDICATIONS AND USAGE

AZOPT® Suspension is a carbonic anhydrase inhibitor (CAI) indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Dosage and Administration

The recommended dose is one drop of AZOPT® Suspension in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart.

IMPORTANT SAFETY INFORMATION

Contraindications

AZOPT® Suspension is contraindicated in patients who are hypersensitive to any component of this product.

Warnings and Precautions

Sulfonamide Hypersensitivity Reactions - AZOPT® Suspension is a sulfonamide and although administered topically it is absorbed systemically. The same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of AZOPT® Suspension. Fatalities have occurred, although rarely, due to severe reactions to

not known. While treatment with TRAVATAN Z® Solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Eyelash Changes -TRAVATAN Z® Solution may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation - TRAVATAN Z® Solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Macular Edema - Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. TRAVATAN Z® Solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Angle-closure, Inflammatory or Neovascular Glaucoma - TRAVATAN Z® Solution has not been evaluated for the treatment of angle-closure, inflammatory or neovascular glaucoma.

Bacterial Keratitis - There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial.

Use with Contact Lenses - Contact lenses should be removed prior to instillation of TRAVATAN Z® Solution and may be reinserted 15 minutes following its administration.

Adverse Reactions

The most common adverse reaction observed in controlled clinical studies with TRAVATAN Z® Solution was ocular hyperemia which was reported in 30 to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyperemia. Ocular adverse reactions reported at an incidence of 5 to 10% in these clinical studies included decreased visual acuity, eye discomfort, foreign body sensation, pain and pruritus. In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.

Use in Specific Populations

Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

Click here for full prescribing information for TRAVATAN Z® Solution

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

Corneal Endothelium—There is an increased potential for developing corneal edema in patients with low endothelial cell counts.

Severe Hepatic or Renal Impairment (CrCl < 30 mL/min)—SIMBRINZA® Suspension has not been specifically studied in these patients and is not recommended.

Acute Angle-Closure Glaucoma—The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. SIMBRINZA® Suspension has not been studied in patients with acute angle-closure glaucoma.

Contact Lens Wear—The preservative in SIMBRINZA® Suspension, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of SIMBRINZA® Suspension but may be reinserted 15 minutes after instillation.

Severe Cardiovascular Disease—Brimonidine tartrate, a component of SIMBRINZA® Suspension, had a less than 5% mean decrease in blood pressure 2 hours after dosing in clinical studies; caution should be exercised in treating patients with severe cardiovascular disease.

Potentiation of Vascular Insufficiency—Brimonidine tartrate, a component of SIMBRINZA® Suspension, may potentiate syndromes associated with vascular insufficiency. It should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or Thromboangiitis obliterans.

Contamination of Topical Ophthalmic Products After Use—There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers have been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Adverse Reactions

SIMBRINZA® Suspension

In two clinical trials of 3 months' duration with SIMBRINZA® Suspension, the most frequent reactions associated with its use occurring in approximately 3-5% of patients in descending order of incidence included: blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, and eye allergy. Adverse reaction rates with SIMBRINZA® Suspension were comparable to those of the individual components. Treatment discontinuation, mainly due to adverse reactions, was reported in 11% of SIMBRINZA® Suspension patients.

Brinzolamide 1%

In clinical studies of brinzolamide ophthalmic suspension 1%, the most frequently reported

Corneal Endothelium - Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium. There is an increased potential for developing corneal edema in patients with low endothelial cell counts. Caution should be used when prescribing AZOPT® Suspension to this group of patients.

Severe Renal Impairment - AZOPT® Suspension has not been studied in patients with severe renal impairment (CrCl ≥ 30 mL/min). Because AZOPT® Suspension and its metabolite are excreted predominantly by the kidney, AZOPT® Suspension is not recommended in such patients.

Acute Angle-Closure Glaucoma - The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. AZOPT® Suspension has not been studied in patients with acute angle-closure glaucoma.

Contact Lens Wear - The preservative in AZOPT® Suspension, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation, but may be reinserted 15 minutes after instillation.

Adverse Reactions

In clinical studies of AZOPT® Suspension, the most frequently reported adverse events reported in 5-10% of patients were blurred vision and bitter, sour or unusual taste. Adverse events occurring in 1-5% of patients were blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus and rhinitis.

Drug Interactions

Oral Carbonic Anhydrase Inhibitors - There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral CAI and AZOPT® Suspension. The concomitant administration of AZOPT® Suspension and oral CAIs is not recommended.

High-Dose Salicylate Therapy - In patients treated with oral CAIs, rare instances of acidbase alterations have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interactions should be considered in patients receiving AZOPT® Suspension.

Click here for full prescribing information for AZOPT® Suspension

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

rhinitis.

Brimonidine Tartrate 0.2%

In clinical studies of brimonidine tartrate 0.2%, adverse events occurring in approximately 10–30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus.

Events occurring in approximately 3-9% of the subjects, in descending order, included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision, and muscular pain.

Drug Interactions—Consider the following when prescribing SIMBRINZA® Suspension:

Concomitant administration with oral carbonic anhydrase inhibitors is not recommended due to the potential additive effect. Use with high-dose salicylate may result in acid-base and electrolyte alterations. Use with CNS depressants may result in an additive or potentiating effect. Use with antihypertensives/cardiac glycosides may result in additive or potentiating effect on lowering blood pressure. Use with tricyclic antidepressants may blunt the hypotensive effect of systemic clonidine and it is unknown if use with this class of drugs interferes with IOP lowering. Use with monoamine oxidase inhibitors may result in increased hypotension.

Click here for full prescribing information for SIMBRINZA® Suspension

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*This offer is not valid for patients who are enrolled in Medicare Part D, Medicaid, Medigap, VA, DOD, Tricare, or any other government-run or government-sponsored health care program with a pharmacy benefit. Additional terms and conditions apply. See savings card material for details. If you are not eligible for the savings card, you can still enjoy other benefits of the OPENINGS® Patient Support Program.